VALN - מכפיל P/S עתידי Valneva Pharma
Unique vaccine patents and stringent FDA oversight create a powerful defensive barrier for Valneva SE. The future P/S multiple visualizes this potential, with the current level sitting around 3.30. However, cash flow volatility stemming from government contracts creates risks that are offset by high geopolitical resilience and support from Western governments.
VALN (Valneva Vaccines): פילוחים אנליטיים ודוחות לפי אינדיקטורים
When screening the reliability of Valneva SE (VALN), investors evaluate the ratio of market value to projected sales. This metric compares current market capitalization with expected turnover to identify any overpayment for future earnings. For this vaccine developer, the calculation accounts for environmental safety costs of production facilities and biohazardous waste disposal. The trend of the future P/S multiple on the GURU.Markets platform helps determine the risk of asset impairment.
